ONCORESPONSE
OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, to interrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive ... immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer.
ONCORESPONSE
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2015-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.oncoresponseinc.com
Total Employee:
11+
Status:
Active
Contact:
206-805-1600
Email Addresses:
[email protected]
Total Funding:
103.1 M USD
Technology used in webpage:
SPF Domain Not Resolving Euro Microsoft Exchange Online Office 365 Mail GoDaddy DNS GoDaddy Zoom Video Conferencing Zoom KnowBe4
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-11-07 | Paganini Biopharma | Paganini Biopharma acquired by OncoResponse | N/A |
Investors List
Bering Capital
Bering Capital investment in Series C - OncoResponse
ARCH Venture Partners
ARCH Venture Partners investment in Series C - OncoResponse
RiverVest
RiverVest investment in Series C - OncoResponse
Qatar Investment Authority
Qatar Investment Authority investment in Series C - OncoResponse
Canaan Partners
Canaan Partners investment in Series C - OncoResponse
Redmile Group
Redmile Group investment in Series C - OncoResponse
Yonjin Venture
Yonjin Venture investment in Series C - OncoResponse
3B Future Health Fund
3B Future Health Fund investment in Series C - OncoResponse
Magnetar Capital
Magnetar Capital investment in Series C - OncoResponse
Qatar Investment Authority
Qatar Investment Authority investment in Series B - OncoResponse
Official Site Inspections
http://www.oncoresponseinc.com
- Host name: 132.44.180.107.host.secureserver.net
- IP address: 107.180.44.132
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
